124 related articles for article (PubMed ID: 3308485)
1. Establishment of human ovarian tumour lines in nude mice and their responses to platinum analogues.
Sawada M; Ozaki M; Mori Y; Taniguchi H; Tateishi R; Wada A
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1219-23. PubMed ID: 3308485
[No Abstract] [Full Text] [Related]
2. [Antitumor activity of platinum analogs against human ovarian tumors heterotransplanted into nude mice].
Sawada M; Ozaki M; Hongo J; Hirota Y; Inagaki M; Taniguchi H; Tateishi R; Mori Y
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):693-8. PubMed ID: 3548596
[TBL] [Abstract][Full Text] [Related]
3. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
Boven E; van der Vijgh WJ; Nauta MM; Schlüper HM; Pinedo HM
Cancer Res; 1985 Jan; 45(1):86-90. PubMed ID: 4038381
[TBL] [Abstract][Full Text] [Related]
4. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
5. Antitumour activity of platinum analogues against human yolk sac tumours heterotransplanted in nude mice.
Sawada M; Matsui Y; Okudaira Y
Br J Cancer; 1986 Mar; 53(3):415-7. PubMed ID: 3516194
[No Abstract] [Full Text] [Related]
6. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs.
Harrap KR; Jones M; Siracky J; Pollard LA; Kelland LR
Ann Oncol; 1990; 1(1):65-76. PubMed ID: 2078487
[TBL] [Abstract][Full Text] [Related]
7. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
[TBL] [Abstract][Full Text] [Related]
8. [Effect of a newly developed platinum compound cis-1, 1-cyclobutane dicarboxylato-(2R)-2-methyl-1,4-butane diamine platinum (II), on human ovarian tumors transplanted into nude mice].
Sawada M; Ozaki M; Taniguchi H; Tateishi R; Mori Y; Mino K
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 1):637-41. PubMed ID: 3355185
[TBL] [Abstract][Full Text] [Related]
9. Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin.
Drees M; Dengler WM; Hendriks HR; Kelland LR; Fiebig HH
Eur J Cancer; 1995; 31A(3):356-61. PubMed ID: 7786602
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin substitution for cisplatin in the treatment of ovarian carcinoma--a word of caution.
McGuire WP; Abeloff MD
J Natl Cancer Inst; 1989 Oct; 81(19):1438-9. PubMed ID: 2674458
[No Abstract] [Full Text] [Related]
11. Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice.
Boven E; Nauta MM; Schluper HM; Elferink F; van der Vijgh WJ; Pinedo HM
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1253-60. PubMed ID: 4076289
[TBL] [Abstract][Full Text] [Related]
12. [Antitumor effect of carboplatin and iproplatin on human urinary bladder and prostatic cancers grown in nude mice].
Hasegawa J; Kawamura N; Yamada S; Tsuboi N; Akimoto M
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3279-83. PubMed ID: 3318705
[TBL] [Abstract][Full Text] [Related]
13. Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models.
Lin X; Zhang Q; Rice JR; Stewart DR; Nowotnik DP; Howell SB
Eur J Cancer; 2004 Jan; 40(2):291-7. PubMed ID: 14728945
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of cisplatin analogs against malignant ovarian tumor xenografts into nude mice.
Hamaguchi K; Miyahara K; Nishimura H; Tashiro M; Kishi N; Matsumura T; Yakushiji M; Kato T
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Nov; 40(11):1755-9. PubMed ID: 3069943
[TBL] [Abstract][Full Text] [Related]
15. Comparative intraperitoneal pharmacokinetics of three platinum analogues.
Lind MJ; Murphy DJ; Sharma H; Tinker N; Smith A; McAuliffe CA; Crowther D
Cancer Chemother Pharmacol; 1991; 28(4):315-7. PubMed ID: 1879050
[TBL] [Abstract][Full Text] [Related]
16. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines.
Perez RP; Perez KM; Handel LM; Hamilton TC
Cancer Chemother Pharmacol; 1992; 29(6):430-4. PubMed ID: 1568285
[TBL] [Abstract][Full Text] [Related]
17. The role of platinum dose intensity in the management of ovarian cancer.
Markman M
J Cancer Res Clin Oncol; 1993; 119(9):511-2. PubMed ID: 8325902
[No Abstract] [Full Text] [Related]
18. Optimal dosing with carboplatin.
Ozols RF
Semin Oncol; 1989 Apr; 16(2 Suppl 5):14-8. PubMed ID: 2655094
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin.
Med Lett Drugs Ther; 1989 Sep; 31(800):83-4. PubMed ID: 2671623
[No Abstract] [Full Text] [Related]
20. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.
Kelland LR; Jones M; Abel G; Valenti M; Gwynne J; Harrap KR
Cancer Chemother Pharmacol; 1992; 30(1):43-50. PubMed ID: 1586979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
